Your Article Summary
See Latest ArticlesMeta-analysis: beta-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure
Annals of Internal Medicine, 06/03/09
McAlister FA et al. - This meta-regression analyses of beta-blocker heart failure trials demonstrate that the magnitude of survival benefit seen with beta-blockers is statistically significantly associated with the magnitude of heart rate reduction achieved but not the dosage of beta-blocker administered. However, because no heart failure trials have randomly assigned participants who receive beta-blockers to different target heart rates and the authors did not find an inflection point in this meta-regression for heart rate reduction, the optimal heart rate (and thus target heart rate reduction) is unknown. Thus, 2 questions remain unanswered: Is there any additional benefit to up-titrating beta-blocker dose to trial doses if substantial heart rate reduction has already been achieved with a lower dose? Is there any additional benefit to increasing beta-blocker dose above trial doses if heart rate reduction is minimal?
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09
Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy
Current Medical Research and Opinion, 11/20/09
Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia
Annals of Internal Medicine, 11/03/09
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
Drug dosage protocol for calcium oxalate stone
Urological Research - Urolithiasis, 10/23/09
Telavancin: A Novel Lipoglycopeptide
Clinical Infectious Diseases, 11/16/09
Risperidone dose for schizophrenia
Cochrane Reviews, 10/21/09